Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History IONS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics IONS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield 2.06 %
Consecutive Years 0
Forward Annual Dividend 0.77 USD
Consistent Years 0
Dividend CAGR 3Y
Continuous Dividends 0
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date 17.02.2000

Ionis Pharmaceuticals Inc

IONS
Current price
37.41 USD +0.4 USD (+1.08%)
Last closed 37.01 USD
ISIN US4622221004
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 5 890 474 496 USD
Yield for 12 month -16.27 %
1Y
3Y
5Y
10Y
15Y
IONS
21.11.2021 - 28.11.2021

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California. Address: 2855 Gazelle Court, Carlsbad, CA, United States, 92010

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

57.66 USD

P/E ratio

Dividend Yield

Financials IONS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures IONS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+705 138 000 USD

Last Year

+787 647 000 USD

Current Quarter

+131 612 000 USD

Last Quarter

+226 576 000 USD

Current Year

+693 923 000 USD

Last Year

+778 514 000 USD

Current Quarter

+130 149 000 USD

Last Quarter

+222 746 000 USD
EBITDA -460 854 016 USD
Operating Margin TTM -111.59 %
Price to Earnings
Return On Assets TTM -10.59 %
PEG Ratio 25.70
Return On Equity TTM -118.62 %
Wall Street Target Price 57.66 USD
Revenue TTM 717 252 992 USD
Book Value 2.99 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 10.10 %
Dividend Yield
Gross Profit TTM -181 148 000 USD
Earnings per share -2.99 USD
Diluted Eps TTM -2.99 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -43.70 %
Profit Margin -63.86 %

Stock Valuation IONS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 90.91
Enterprise Value Revenue 7.19
Price Sales TTM 8.21
Enterprise Value EBITDA -22.08
Price Book MRQ 12.38

Technical indicators IONS

For 52 weeks

23.95 USD 52.34 USD
50 Day MA 32.32 USD
Shares Short Prior Month 15 266 156
200 Day MA 35.11 USD
Short Ratio 9.36
Shares Short 14 836 205
Short Percent 12.37 %